U.S. Inhaler Rule Change Prompts India Race For Advair Generic Approvals
This article was originally published in PharmAsia News
Executive Summary
Relaxed U.S. rules governing inhalers coupled with generic drugs have opened a chase among India's Cipla, Glenmark, Lupin and Sun Pharma for the $5 billion-a-year U.S. market for GlaxoSmithKline's Advair (fluticasone/salmeterol).